Ignite Creation Date:
2024-05-06 @ 7:01 PM
Last Modification Date:
2024-10-26 @ 2:58 PM
Study NCT ID:
NCT05863260
Status:
RECRUITING
Last Update Posted:
2023-05-18
First Post:
2023-05-09
Brief Title:
Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
Tislelizumab Anti-PD-1 Combined With Definitive Chemoradiotherapy in Recurrent Cervical Cancer PILOT-2020-511 a Single-arm Phase 2 Trial
Status:
RECRUITING
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Tislelizumab combined with chemoradiotherapy in the treatment of recurrent metastasis cervical cancer a single armsingle center phase ii and observational clinical study
Detailed Description:
Tislelizumab combined with chemoradiotherapy in the treatment of recurrent metastasis cervical cancer a single armsingle center phase ii and observational clinical study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None